1
|
Manetti D, Garifulina A, Bartolucci G, Bazzicalupi C, Bellucci C, Chiaramonte N, Dei S, Di Cesare Mannelli L, Ghelardini C, Gratteri P, Spirova E, Shelukhina I, Teodori E, Varani K, Tsetlin V, Romanelli MN. New Rigid Nicotine Analogues, Carrying a Norbornane Moiety, Are Potent Agonists of α7 and α3* Nicotinic Receptors. J Med Chem 2019; 62:1887-1901. [PMID: 30681854 DOI: 10.1021/acs.jmedchem.8b01372] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
A three-dimensional database search has been applied to design a series of endo- and exo-3-(pyridin-3-yl)bicyclo[2.2.1]heptan-2-amines as nicotinic receptor ligands. The synthesized compounds were tested in radioligand binding assay on rat cortex against [3H]-cytisine and [3H]-methyllycaconitine to measure their affinity for α4β2* and α7* nicotinic receptors. The new derivatives showed some preference for the α4β2* over the α7* subtype, with their affinity being dependent on the endo/exo isomerism and on the methylation degree of the basic nitrogen. The endo primary amines displayed the lowest Ki values on both receptor subtypes. Selected compounds (1a, 2a, 3a, and 6a) were tested on heterologously expressed α4β2, α7, and α3β2 receptors and on SHSY-5Y cells. Compounds 1a and 2a showed α4β2 antagonistic properties while behaved as full agonists on recombinant α7 and on SHSY5Y cells. On the α3β2 subtype, only the chloro derivative 2a showed full agonist activity and submicromolar potency (EC50 = 0.43 μM). The primary amines described here represent new chemotypes for the α7 and α3* receptor subtypes.
Collapse
Affiliation(s)
- Dina Manetti
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Alexandra Garifulina
- Department of Molecular Basis of Neurosignaling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry , Russian Academy of Sciences , Miklukho-Maklaya Street 16/10 , 117997 Moscow , Russia
| | - Gianluca Bartolucci
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Carla Bazzicalupi
- Department of Chemistry "Ugo Schiff" , University of Florence , Via della Lastruccia 3 , 50019 Sesto Fiorentino , Italy
| | - Cristina Bellucci
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Niccolò Chiaramonte
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Silvia Dei
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Lorenzo Di Cesare Mannelli
- Department of NEUROFARBA, Section of Pharmacology and Toxicology , University of Florence , Viale G Pieraccini 6 , 50139 Firenze , Italy
| | - Carla Ghelardini
- Department of NEUROFARBA, Section of Pharmacology and Toxicology , University of Florence , Viale G Pieraccini 6 , 50139 Firenze , Italy
| | - Paola Gratteri
- Department of NEUROFARBA, Laboratory of Molecular Modeling Cheminformatics & QSAR , University of Firenze , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Ekaterina Spirova
- Department of Molecular Basis of Neurosignaling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry , Russian Academy of Sciences , Miklukho-Maklaya Street 16/10 , 117997 Moscow , Russia
| | - Irina Shelukhina
- Department of Molecular Basis of Neurosignaling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry , Russian Academy of Sciences , Miklukho-Maklaya Street 16/10 , 117997 Moscow , Russia
| | - Elisabetta Teodori
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| | - Katia Varani
- Institute of Pharmacology , University of Ferrara , Via Fossato di Mortara 17-19 , 44100 Ferrara , Italy
| | - Victor Tsetlin
- Department of Molecular Basis of Neurosignaling, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry , Russian Academy of Sciences , Miklukho-Maklaya Street 16/10 , 117997 Moscow , Russia
| | - Maria Novella Romanelli
- Department of Neuroscience, Psychology, Drug Research and Child's Health (NEUROFARBA), Section of Pharmaceutical and Nutraceutical Sciences , University of Florence , Via Ugo Schiff 6 , 50019 Sesto Fiorentino , Italy
| |
Collapse
|
2
|
Manetti D, Bellucci C, Dei S, Teodori E, Varani K, Spirova E, Kudryavtsev D, Shelukhina I, Tsetlin V, Romanelli MN. New quinoline derivatives as nicotinic receptor modulators. Eur J Med Chem 2016; 110:246-58. [DOI: 10.1016/j.ejmech.2016.01.025] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2015] [Revised: 01/14/2016] [Accepted: 01/15/2016] [Indexed: 11/30/2022]
|
3
|
Rombouts JA, Veenboer RP, Villellas C, Lu P, Ehlers AW, Andries K, Koul A, Lill H, Ruijter E, Orru RVA, Lammertsma K, Bald D, Slootweg JC. Synthesis, characterization and biological activity of fluorescently labeled bedaquiline analogues. RSC Adv 2016. [DOI: 10.1039/c6ra22693k] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Labeling the tuberculosis drug bedaquiline with a fluorescent alkynyl-BODIPY moiety does not disrupt its antibacterial properties.
Collapse
|
4
|
Computational studies of novel carbonyl-containing diazabicyclic ligands interacting with α4β2 nicotinic acetylcholine receptor (nAChR) reveal alternative binding modes. Bioorg Med Chem Lett 2013; 23:5105-13. [DOI: 10.1016/j.bmcl.2013.07.028] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2013] [Revised: 07/05/2013] [Accepted: 07/16/2013] [Indexed: 11/22/2022]
|
5
|
Mazurov AA, Kombo DC, Hauser TA, Miao L, Dull G, Genus JF, Fedorov NB, Benson L, Sidach S, Xiao Y, Hammond PS, James JW, Miller CH, Yohannes D. Discovery of (2S,3R)-N-[2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzo[b]furan-2-carboxamide (TC-5619), a Selective α7 Nicotinic Acetylcholine Receptor Agonist, for the Treatment of Cognitive Disorders. J Med Chem 2012; 55:9793-809. [DOI: 10.1021/jm301048a] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Anatoly A. Mazurov
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - David C. Kombo
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Terry A. Hauser
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Lan Miao
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Gary Dull
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - John F. Genus
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Nikolai B. Fedorov
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Lisa Benson
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Serguei Sidach
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Yunde Xiao
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Philip S. Hammond
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - John W. James
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Craig H. Miller
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| | - Daniel Yohannes
- Targacept, Inc., Winston-Salem, North
Carolina 27101-4165,
United States
| |
Collapse
|
6
|
Mazurov AA, Miao L, Bhatti BS, Strachan JP, Akireddy S, Murthy S, Kombo D, Xiao YD, Hammond P, Zhang J, Hauser TA, Jordan KG, Miller CH, Speake JD, Gatto GJ, Yohannes D. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. J Med Chem 2012; 55:9181-94. [PMID: 22793665 DOI: 10.1021/jm3006542] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Diversification of essential nicotinic cholinergic pharmacophoric elements, i.e., cationic center and hydrogen bond acceptor, resulted in the discovery of novel potent α4β2 nAChR selective agonists comprising a series of N-acyldiazabicycles. Core characteristics of the series are an exocyclic carbonyl moiety as a hydrogen bond acceptor and endocyclic secondary amino group. These features are positioned at optimal distance and with optimal relative spatial orientation to provide near optimal interactions with the receptor. A novel potent and highly selective α4β2 nAChR agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, TC-6683, AZD1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for Alzheimer's disease.
Collapse
Affiliation(s)
- Anatoly A Mazurov
- Targacept, Inc., Winston Salem, North Carolina 27101, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Yu LF, Tückmantel W, Eaton JB, Caldarone B, Fedolak A, Hanania T, Brunner D, Lukas RJ, Kozikowski AP. Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity. J Med Chem 2012; 55:812-23. [PMID: 22148173 DOI: 10.1021/jm201301h] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
There is considerable evidence to support the hypothesis that the blockade of nAChR is responsible for the antidepressant action of nicotinic ligands. The nicotinic acetylcholine receptor (nAChR) antagonist, mecamylamine, has been shown to be an effective add-on in patients that do not respond to selective serotonin reuptake inhibitors. This suggests that nAChR ligands may address an unmet clinical need by providing relief from depressive symptoms in refractory patients. In this study, a new series of nAChR ligands based on an isoxazole-ether scaffold have been designed and synthesized for binding and functional assays. Preliminary structure-activity relationship (SAR) efforts identified a lead compound 43, which possesses potent antidepressant-like activity (1 mg/kg, IP; 5 mg/kg, PO) in the classical mouse forced swim test. Early stage absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) studies also suggested favorable drug-like properties, and broad screening toward other common neurotransmitter receptors indicated that compound 43 is highly selective for nAChRs over the other 45 neurotransmitter receptors and transporters tested.
Collapse
Affiliation(s)
- Li-Fang Yu
- Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, United States
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Liu J, Eaton JB, Caldarone B, Lukas RJ, Kozikowski AP. Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (Sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists. J Med Chem 2010; 53:6973-85. [PMID: 20822184 DOI: 10.1021/jm100765u] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
In order to advance therapeutic applications of nicotinic ligands, continuing research efforts are being directed toward the identification and characterization of novel nicotinic acetylcholine receptor (nAChR) ligands that are both potent and subtype selective. Herein we report the synthesis and pharmacological evaluation of members of a new series of 3-alkoxy-5-aminopyridine derivatives that display good selectivity for the α4β2-nAChR subtype based on ligand binding and functional evaluations. The most potent ligand in this series, compound 64, showed high radioligand binding affinity and selectivity for rat α4β2-nAChR with a K(i) value of 1.2 nM and 4700-fold selectivity for α4β2- over α3β4-nAChR, and ∼100-fold selectivity for functional, high-sensitivity, human α4β2-nAChR over α3β4*-nAChR. In the mouse forced swim test, compound 64 exhibited antidepressant-like effects. Structure-activity relationship (SAR) analyses suggest that the introduction of additional substituents to the amino group present on the pyridine ring of the N-demethylated analogue of compound 17 can provide potent α4β2-nAChR-selective ligands for possible use in treatment of neurological and psychiatric disorders including depression.
Collapse
Affiliation(s)
- Jianhua Liu
- Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 833 South Wood Street, Chicago, Illinois 60612, USA
| | | | | | | | | |
Collapse
|
9
|
Design of novel α7-subtype-preferring nicotinic acetylcholine receptor agonists: Application of docking and MM-PBSA computational approaches, synthetic and pharmacological studies. Bioorg Med Chem Lett 2009; 19:6353-7. [DOI: 10.1016/j.bmcl.2009.09.073] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2009] [Revised: 09/11/2009] [Accepted: 09/18/2009] [Indexed: 11/19/2022]
|
10
|
Guandalini L, Norcini M, Varani K, Pistolozzi M, Gotti C, Bazzicalupi C, Martini E, Dei S, Manetti D, Scapecchi S, Teodori E, Bertucci C, Ghelardini C, Romanelli MN. Design, Synthesis, and Preliminary Pharmacological Evaluation of New Quinoline Derivatives as Nicotinic Ligands. J Med Chem 2007; 50:4993-5002. [PMID: 17850058 DOI: 10.1021/jm070325r] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A series of nicotinic ligands, carrying a quinoline nucleus, and characterized by a pharmacophoric distance between the quinoline nitrogen (H-bond acceptor) and the cationic nitrogen atoms higher than that proposed in the classical pharmacophoric models, have been synthesized and tested for their affinity for the central nicotinic receptor. The enantiomers of the nicotine analogue 1-methyl-2-pyrrolidinyl-6-quinoline and of its methiodide display enantioselectivity in binding studies, but not when tested in vivo; on alpha7* nicotinic receptor enantioselectivity is inverted with respect to the alpha4beta2* subtype. N,N,N-Trimethyl-4-(quinolin-6-yl)but-3-yn-1-ammonium iodide (3c) and trans-N,N,N-trimethyl-4-(quinolin-6-yl)but-3-en-1-ammonium iodide (4c), showing pharmacophoric distances in the range 8.5-10.4 A, interact with the alpha4beta2* nicotinic receptor with Ki in the microM range; compound 3c shows preference for the alpha7* subtype.
Collapse
Affiliation(s)
- Luca Guandalini
- Laboratory of Design, Synthesis and Study of Biologically Active Heterocycles (HeteroBioLab), Department of Pharmaceutical Sciences, University of Florence, via Ugo Schiff 6, I-50019 Sesto Fiorentino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F. Central Nicotinic Receptors: Structure, Function, Ligands, and Therapeutic Potential. ChemMedChem 2007; 2:746-67. [PMID: 17295372 DOI: 10.1002/cmdc.200600207] [Citation(s) in RCA: 145] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The growing interest in nicotinic receptors, because of their wide expression in neuronal and non-neuronal tissues and their involvement in several important CNS pathologies, has stimulated the synthesis of a high number of ligands able to modulate their function. These membrane proteins appear to be highly heterogeneous, and still only incomplete information is available on their structure, subunit composition, and stoichiometry. This is due to the lack of selective ligands to study the role of nAChR under physiological or pathological conditions; so far, only compounds showing selectivity between alpha4beta2 and alpha7 receptors have been obtained. The nicotinic receptor ligands have been designed starting from lead compounds from natural sources such as nicotine, cytisine, or epibatidine, and, more recently, through the high-throughput screening of chemical libraries. This review focuses on the structure of the new agonists, antagonists, and allosteric ligands of nicotinic receptors, it highlights the current knowledge on the binding site models as a molecular modeling approach to design new compounds, and it discusses the nAChR modulators which have entered clinical trials.
Collapse
Affiliation(s)
- M Novella Romanelli
- Laboratory of Design, Synthesis, and Study of Biologically Active Heterocycles (HeteroBioLab), Department of Pharmaceutical Sciences, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy.
| | | | | | | | | | | |
Collapse
|
12
|
Novellino E, Cosimelli B, Ehlardo M, Greco G, Iadanza M, Lavecchia A, Rimoli MG, Sala A, Da Settimo A, Primofiore G, Da Settimo F, Taliani S, La Motta C, Klotz KN, Tuscano D, Trincavelli ML, Martini C. 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. J Med Chem 2006; 48:8253-60. [PMID: 16366607 DOI: 10.1021/jm050792d] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Cambridge Structural Database (CSD) was searched through two 3D queries based on substructures shared by well-known antagonists at the A(1) and A(3) adenosine receptors (ARs). Among the resulting 557 hits found in the CSD, we selected five compounds to purchase, synthesize, or translate synthetically into analogues better tailored to interact with the biological targets. Binding experiments using human ARs showed that four out of five tested compounds turned out to be antagonists at the A(1)AR or A(3)AR with K(i) values between 50 and 440 nM. Lead optimizations of 2-(benzimidazol-2-yl)quinoxalines (BIQs, 3) gave the best results in terms of potency and selectivity at the A(1) and A(3) ARs. Particularly, 2-(4-ethylthiobenzimidazol-2-yl)quinoxaline (3e) exhibited K(i) values at the A(1)AR, A(2A)AR, and A(3)AR of 0.5, 3440, and 955 nM, respectively, whereas 2-(4-methylbenzimidazol-2-yl)quinoxaline (3b) displayed at the same ARs K(i) values of 8000, 833, and 26 nM, respectively.
Collapse
Affiliation(s)
- Ettore Novellino
- Dipartimento di Chimica Farmaceutica e Tossicologica, Università di Napoli "Federico II", Via D. Montesano, 49, 80131 Napoli, Italy. novellin.unima.it
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|